HRMY is a stock, not an exchange-traded fund. The central target used here is the arithmetic mean of 12 verified analyst price targets, rounded to $48. The individual targets span a wide range from $30 to roughly $70, a gap that reflects sharply divided views on the company's long-term trajectory.
On the cautious side, Bank of America's Jason Gerberry has maintained an Underperform rating with a $30 target, while Truist's Danielle Brill and UBS sit near the low-to-mid range with Hold or Neutral ratings. In the middle, Deutsche Bank holds a $42 target. The more bullish cohort includes H.C. Wainwright at $55, Ladenburg Thalmann at $55, Wolfe Research at $60, and Oppenheimer at the top of the range near $70 to $72. Mizuho and Needham cluster in the $50 to $51 area.
The dispersion is meaningful. Bulls emphasize the durability of WAKIX demand and pipeline diversification, while bears focus on concentration risk and patent erosion. Notably, the average analyst price target should not be read as a guarantee; it is a central tendency across genuinely divergent outlooks.
Harmony Biosciences Holdings recently traded near $36, within a 52-week range of roughly $26 to $43. Reaching $48 would require an advance of about 33%, a substantial move that would take the shares to a fresh multi-year high.
The path hinges on continued WAKIX growth. The company reported second-quarter 2026 revenue of about $261 million, up roughly 30% year over year, and reaffirmed 2026 net revenue guidance of $1.0 billion to $1.04 billion. With a forward P/E (price-to-earnings ratio) near 9 and a strong balance sheet, the valuation does not appear demanding relative to profitable biotech peers, but investors are weighing near-term execution against the eventual loss of WAKIX exclusivity.
Several fundamentals could justify a higher valuation. WAKIX, the company's commercial therapy for narcolepsy, continues to post strong revenue growth and expanded its label. Management is pursuing lifecycle extensions, including a high-dose formulation of pitolisant, and has built a pipeline spanning Prader-Willi syndrome, myotonic dystrophy, Fragile X syndrome, and rare epilepsies through acquisitions such as Epygenix Therapeutics.
The company is profitable, holds roughly $880 million in cash and investments, and generates healthy free cash flow. Analysts who favor the stock argue this financial flexibility lets Harmony fund development and pursue business development without diluting shareholders, reducing single-asset risk over time. A planned CEO transition to Peter Anastasiou has drawn a measured but generally non-disruptive reception.
The central risk is concentration: nearly all current revenue comes from WAKIX, and pitolisant faces a patent cliff later this decade. If generic competition arrives sooner than expected or lifecycle extensions are delayed, revenue growth could decelerate sharply and trigger valuation compression.
Competition in sleep and wakefulness disorders is intensifying, including oxybate-based therapies and other wake-promoting agents from larger pharmaceutical companies. Regulatory outcomes for new indications, such as idiopathic hypersomnia, remain uncertain. A disappointing earnings print, a guidance cut, or a clinical setback could also weigh on the stock, which remains exposed to single-drug sentiment swings.
The shares have consolidated between roughly $35 and $43 in recent months, with the upper bound near the 52-week high acting as a resistance level. A sustained move through the low-to-mid $40s would mark a breakout zone, while the mid-$30s has served as an area of demand. The $48 target sits just above the current resistance level, so it would require a decisive breakout rather than a continuation of the recent range-bound pattern.
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms do not always state a uniform timeline. Investors should watch the third-quarter 2026 earnings report, guidance updates, WAKIX prescription trends, regulatory milestones for new indications, and any analyst target revisions. Patent and competitive developments, as well as pipeline data readouts, are the other key catalysts for the stock forecast.
For traders seeking a systematic layer on top of fundamental research, Tickeron's AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. As you evaluate whether HRMY can sustain momentum toward higher levels, consider pairing these signals with your own research.
The question of whether Harmony Biosciences can reach $48 turns on execution and time horizon. The target, an average of 12 analyst price targets, implies a substantial roughly 33% gain from recent levels and sits above the stock's current resistance zone. Support comes from a growing, profitable WAKIX franchise, a solid balance sheet, and a broadening pipeline. The obstacles are equally real: single-drug concentration, a looming patent cliff, and competitive and regulatory uncertainty. With analyst targets ranging from $30 to roughly $70, the wide dispersion is itself the key takeaway, investors are pricing a genuine fork in the road rather than a consensus about the outcome.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, HRMY has been loosely correlated with SNDX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if HRMY jumps, then SNDX could also see price increases.
| Ticker / NAME | Correlation To HRMY | 1D Price Change % | ||
|---|---|---|---|---|
| HRMY | 100% | -0.68% | ||
| SNDX - HRMY | 36% Loosely correlated | -0.63% | ||
| KURA - HRMY | 35% Loosely correlated | N/A | ||
| EXEL - HRMY | 34% Loosely correlated | -1.62% | ||
| KROS - HRMY | 34% Loosely correlated | +1.74% | ||
| RXRX - HRMY | 33% Loosely correlated | -6.70% | ||
More | ||||